Daclizumab inhibits CD40L expression independently of cell division in memory CD4+ T cells
| CD45RA . | Cell divisions at 48 hrs . | Total . | ||
|---|---|---|---|---|
| % Divided . | 2 . | 1 . | 0 . | |
| Control | 7 (4) | 54 (4) | 40 (6) | 100% |
| Daclizumab | 0 | 37 (6) | 64 (6) | 100% |
| % CD40L+ | 2 | 1 | 0 | Total |
| Control | 5 (3) | 38 (6) | 20 (2) | 63% |
| Daclizumab | 0 | 13 (5) | 14 (3) | 27% |
| CD45RA . | Cell divisions at 48 hrs . | Total . | ||
|---|---|---|---|---|
| % Divided . | 2 . | 1 . | 0 . | |
| Control | 7 (4) | 54 (4) | 40 (6) | 100% |
| Daclizumab | 0 | 37 (6) | 64 (6) | 100% |
| % CD40L+ | 2 | 1 | 0 | Total |
| Control | 5 (3) | 38 (6) | 20 (2) | 63% |
| Daclizumab | 0 | 13 (5) | 14 (3) | 27% |
Results shown are mean (± SE) of 4 donors.